✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Quick Answer: Blood monitoring is non-optional on TRT or any testosterone-based protocol. The minimum panel is: total testosterone, free testosterone, estradiol, haematocrit, full blood count, PSA (if over 40), and lipid panel. Draw at the mid-cycle trough (3.5 days after your last injection if injecting twice weekly) for a clinically meaningful baseline. This guide covers which markers to test, why each matters, what the numbers mean, and how to adjust your protocol in response.
Why Bloodwork Is Not Optional
Self-managed TRT carries real physiological risks that are entirely manageable with monitoring and entirely dangerous without it. The two most clinically serious are:
- Polycythaemia (elevated haematocrit) — testosterone drives erythropoiesis (red blood cell production). Haematocrit above 54% increases blood viscosity enough to meaningfully raise thrombotic and stroke risk. This is the most common serious adverse event in men on TRT and was flagged in the TRAVERSE trial (NEJM 2023) as a primary safety finding.
- Estradiol dysregulation — both high and low E2 produce symptoms that mirror hypogonadism, making it impossible to optimise a protocol without measuring E2. Starting or adjusting an AI without knowing your actual E2 level is pharmacologically irrational.
Beyond these two, bloodwork establishes your personal baseline, documents your response to TRT, and catches lipid and hepatic changes before they become clinically significant. It is the difference between informed self-management and guesswork.
When to Draw Blood: Timing Is Critical
The most common bloodwork mistake in self-managed TRT is wrong-time sampling. Draw at the wrong point in your injection cycle and you get a number that misrepresents your actual stable serum level.
For Twice-Weekly Injectors (Recommended Protocol)
Draw blood 3.5 days after your last injection — the midpoint between injections. For a Mon/Thu injector, draw on Sunday morning or Wednesday morning. This mid-cycle trough reading reflects the stable, representative serum level that your tissues are actually experiencing most of the time. It is the number to use for dose adjustments and for comparison between blood draws.
For Once-Weekly Injectors
Draw at day 4 or 5 post-injection (the trough). Peak readings (day 1–2) will be misleadingly high and not represent the average exposure your body operates on. Note: once-weekly injection produces wide peak-trough swings; switching to twice-weekly is strongly recommended before spending time optimising a once-weekly protocol.
Time of Day
Draw before 10:00 AM. Testosterone follows a circadian rhythm — morning levels are highest; afternoon and evening levels fall 20–40% from morning peak. For men on TRT, the circadian rhythm is blunted but not eliminated. Consistent morning draws allow accurate comparison between panels.
Fasting State
Fast for 8–12 hours before lipid panel. You do not need to fast for testosterone, E2, haematocrit, or FBC — but since a comprehensive panel usually includes lipids, just fast for the whole draw.
The Core Panel: What to Test and Why
Total Testosterone
The primary efficacy marker. At mid-cycle trough, target 500–900 ng/dL (17.4–31.2 nmol/L). Below 400 ng/dL trough suggests underdosing (or poor injection technique causing depot absorption failure). Above 1,000 ng/dL trough suggests overdosing — increase risk of haematocrit, E2 elevation, and possible cardiovascular risk at very high sustained levels.
Note: total testosterone measures both bound and free T. It is the standard clinical measure and sufficient for most TRT monitoring.
Free Testosterone
The fraction not bound to SHBG or albumin — bioavailable for receptor binding. Particularly important if total T is in range but symptoms persist. High SHBG (common with age, liver disease, hyperthyroidism, alcohol use) binds excess T and leaves free T low despite normal total T. Target: upper quartile of the laboratory reference range. If free T is low with normal total T, SHBG management (reducing exogenous hormone doses or optimising metabolic health) is the lever — not simply increasing T dose.
Estradiol (E2)
Target on TRT: 20–35 pg/mL (73–128 pmol/L). Above 50 pg/mL with symptoms warrants AI intervention. Below 15 pg/mL is excessive suppression — reduce or pause AI. Critically: use the sensitive estradiol assay (LC-MS/MS or IA-estradiol designed for males), not the standard E2 assay optimised for women. Standard immunoassay E2 tests significantly overestimate male E2 at low concentrations, producing falsely elevated readings that cause AI over-prescribing. The sensitive assay is sometimes labelled “Estradiol, Sensitive” or “Estradiol, Ultrasensitive.” Ensure your lab uses this format.
Haematocrit (HCT)
The percentage of red blood cells in whole blood. Normal male range: 38–50%. On TRT:
- Below 52%: acceptable — continue monitoring quarterly
- 52–54%: borderline — increase monitoring frequency; address lifestyle factors (sleep apnoea, dehydration, smoking); consider reducing T dose
- Above 54%: action required — pause TRT until HCT falls below 52%; donate blood (therapeutic phlebotomy) if 54–58%; seek urgent medical review above 58%
Men with pre-existing sleep apnoea, smokers, and men living at high altitude are at highest risk of TRT-induced polycythaemia. Check HCT at baseline, 6 weeks, 3 months, and quarterly thereafter.
Full Blood Count (FBC / CBC)
Beyond HCT, the FBC gives you haemoglobin, red cell count, MCV (red cell size), white cell count, and platelet count. Elevated haemoglobin mirrors HCT as an erythropoiesis marker. Unusually high MCV (macrocytosis) may indicate B12 or folate deficiency — common in men eating high-meat TRT-adjacent diets. Monitor annually after baseline; quarterly if HCT is trending up.
PSA (Prostate-Specific Antigen)
Required for men over 40, and advisable for any man with a family history of prostate cancer. TRT does not cause prostate cancer, but it can accelerate pre-existing subclinical disease by providing androgenic stimulus. Baseline PSA before starting TRT is essential — you need a number to compare against. Monitor annually. Investigate a rise of more than 0.75 ng/mL in the first 12 months or any rise above 4.0 ng/mL.
Lipid Panel
Testosterone generally lowers HDL cholesterol and may mildly raise LDL, depending on dose, ester, and route. SubQ injection and lower doses produce more modest lipid effects than high-dose IM protocols. Monitor at baseline, 6 months, then annually. If HDL drops below 35 mg/dL, review protocol. Adding anastrozole (an AI) can worsen lipid profile for some men — monitor lipids separately if adding AI.
SHBG (Sex Hormone-Binding Globulin)
SHBG binds testosterone with high affinity, making bound T unavailable for receptor activation. High SHBG effectively reduces the impact of any given total testosterone dose. Men with SHBG above 55 nmol/L often benefit from more frequent injection (EOD) to maintain higher free T despite high SHBG binding capacity. Low SHBG (below 20 nmol/L) increases free T bioavailability — these men often aromatise more and require closer E2 monitoring. Check SHBG at baseline and annually.
The landmark TRAVERSE trial enrolled 5,204 men aged 45–80 with symptomatic hypogonadism and pre-existing cardiovascular disease or elevated CV risk. Key bloodwork finding: the TRT group had a significantly higher incidence of haematocrit above 54% (polycythaemia) compared to placebo. This was the primary safety signal — not cardiac events, which were non-inferior to placebo. The message for self-managed TRT: cardiac risk is manageable; haematocrit is the monitoring priority.
The Minimum Monitoring Schedule
| Timepoint | Panel |
|---|---|
| Baseline (before starting TRT) | Total T × 2 (separate mornings), free T, E2 (sensitive), LH, FSH, SHBG, prolactin, FBC/HCT, PSA (if ≥40), lipids, thyroid, hepatic panel |
| Week 6 (first check on TRT) | Total T (mid-cycle), free T, E2 (sensitive), HCT, FBC |
| Month 3 | Total T, free T, E2, HCT, FBC, lipids, PSA |
| Month 6 | Full panel: all of the above + SHBG + hepatic |
| Annually thereafter | Full panel; DEXA if on AI for bone density |
Reading Your Results: Common Scenarios and Responses
Scenario: Total T in range, symptoms persist
Check free T and SHBG. High SHBG is the most common cause of symptomatic hypogonadism despite normal total T. Solutions: switch to EOD injection (higher injection frequency increases free T by maintaining higher average circulating T); consider enclomiphene adjunct to stimulate endogenous T production alongside TRT (used in some protocols). Also check E2 — low E2 from over-AI-use produces symptoms that mimic low T.
Scenario: High T, high E2, water retention
Classic over-dose picture with aromatisation. Reduce T dose by 10–20 mg/week. If E2 above 50 pg/mL with symptoms: add anastrozole 0.25 mg on injection days. Recheck in 6 weeks. See: Anastrozole Protocol for TRT.
Scenario: HCT creeping above 50%
Increase injection frequency (less absorption spike = lower erythropoiesis trigger per injection). Switch from IM to SubQ. Ensure adequate hydration (dehydration concentrates HCT artificially). Donate blood (therapeutic phlebotomy) if HCT reaches 52–53%. If HCT remains above 52% despite frequency increase and phlebotomy, reduce T dose or add low-dose aspirin after hepatic review.
Scenario: PSA rise of 1.0 ng/mL within 12 months
This exceeds the investigation threshold of 0.75 ng/mL/year. Pause TRT and arrange urological review. This does not necessarily mean prostate cancer — benign prostatic hyperplasia (BPH) also responds to testosterone — but it requires investigation before continuing.
Scenario: Lipids worsening (HDL dropping)
Common with IM injection and higher doses. Switch to SubQ. Consider dose reduction. Check AI use — anastrozole can lower HDL in some men. If on exemestane, its mild androgenic activity may worsen the lipid picture differently. Dietary and exercise interventions are first-line before adding lipid-lowering medication to an already-complex protocol.
Frequently Asked Questions
How often should I get bloodwork on TRT?
Minimum: at baseline (before starting), at 6 weeks, at 3 months, at 6 months, then annually. More frequent checks are warranted if: your HCT is trending above 50%, you’ve changed your T dose or injection frequency, you’ve added or changed an AI, or you have symptoms that don’t match your expectations from your protocol.
Can I use home finger-prick tests for TRT monitoring?
Yes, for total testosterone, E2, and some haematology markers — several services (Medichecks, Lets Get Checked, ZRT Laboratory) offer finger-prick panels specifically for TRT monitoring. Quality varies: for E2, confirm the test uses a sensitive assay method, not a standard immunoassay. For HCT, a haematocrit centrifuge or home FBC test from a venous draw is more accurate than finger-prick haematocrit.
My doctor won’t test my E2 on TRT — what can I do?
Self-pay private labs are the practical solution. In the UK, Medichecks, Blue Horizon, and Randox provide TRT monitoring panels without a GP referral. In the US, Discounted Labs, Ulta Labs, and LabCorp Direct allow self-pay TRT panels. In the EU, local private lab networks vary by country. The sensitive E2 assay is specifically worth paying for — standard immunoassay E2 testing frequently produces false highs in male ranges that cause unnecessary AI prescribing.
Should I test LH and FSH on TRT?
Only at baseline (to establish whether hypogonadism is primary or secondary) and potentially when considering TRT discontinuation (to assess pituitary recovery). During active TRT, exogenous testosterone fully suppresses LH and FSH to near-zero — testing them on TRT is clinically uninformative.
Every Medsbase order is covered by Reshipment Assurance — if your package doesn’t arrive within the guaranteed window, we reship at no cost. Worldwide discreet shipping. WHO-GMP-certified manufacturers.
Why order TRT ancillaries from Medsbase?
Medsbase stocks the complete TRT protocol — testosterone gel, anastrozole, hCG, and PCT ancillaries — from WHO-GMP-certified manufacturers. What you get:
- Anastrozole (Anastronat) — E2 management
- HUCOG 5000IU hCG — testicular preservation
- PCT Stack (Clomisign + Tamoxilon) — TRT discontinuation protocol
See the full TRT Buying Guide for complete protocol setup, and the Anastrozole Protocol guide for E2 management detail.
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.